Advancing a broad pipeline of differentiated product candidates for chronic inflammatory diseases.

Development Pipeline

Driving meaningful advances to address chronic inflammation.

We’re committed to evolving immunology, with a pipeline of programs specifically designed to address inflammatory diseases with clear, unmet needs. The disease pathways under investigation by Evommune exert influence on a multitude of disease areas, and the modulation of mast cell, sensory neuron and T-cell activity shows promise in multiple established patient populations.

Program
Target
Indication
  • Discovery
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
IL-18
Atopic Dermatitis Ulcerative Colitis Other Indications
MRGPRX2
Migraine
TLR 7/8
Autoimmune Diseases

Program
Target
IL-18
Indication
Stage
Atopic Dermatitis
Ulcerative Colitis
Other Indications
Phase 2
Phase 1
Phase 1
Program
Target
MRGPRX2
Indication
Stage
Migraine
Phase 2
Program
Target
TLR 7/8
Indication
Stage
Autoimmune Diseases
Pre-Clinical
Pre-Clin.

Learn about our ongoing clinical trials for our investigational therapies.